Predicting pathological complete response in breast cancer early.

www.thelancet.com/oncology Vol 15 December 2014 1415 2 André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fl uorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109–16. 3 Yothers GA, O’Connell MJ, Colangelo L, et al. 5-FU and leucovorin (Lv) with or without oxaliplatin (Ox) for adjuvant treatment of stage II and III colon cancer: Long-term follow-up of NSABP C-07 with survival analysis. American Society for Clinical Oncology Gastrointestinal Cancers Symposium; Orlando, FL, USA; Jan 22–24, 2010. Abstract 401. 4 Chibaudel B, Tournigand C, Bonnetain F, et al. Platinum-sensitivity in metastatic colorectal cancer: towards a defi nition. Eur J Cancer 2013; 49: 3813–20. 5 Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fl uorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used fi rst line. J Clin Oncol 2005; 23: 9441–42. 6 Cassidy J, Clarke S, Díaz-Rubio E, et al. XELOX vs FOLFOX-4 as fi rst-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105: 58–64 7 Miwa M, Ura M, Nishida M, et al. Design of a novel oral fl uoropyrimidine carbamate, capecitabine, which generates 5-fl uorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–81. 8 Yasuno H, Kurasawa M, Yanagisawa M, et al. Predictive markers of capecitabine sensitivity identifi ed from the expression profi le of pyrimidine nucleoside-metabolizing enzymes. Oncol Rep 2013; 29: 451–58. 9 Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fl uorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fl uorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548–57. 10 Yasui H, Muro K, Shimada Y, et al. A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. J Cancer Res Clin Oncol 2014; published online Aug 9. DOI:10.1007/s00432-014-1783-3. 11 Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–11. 12 Kawahara S, Otsuji Y, Nakamura M, et al. Sphingosine kinase 1 plays a role in the upregulation of CD44 expression through extracellular signal-regulated kinase signaling in human colon cancer cells. Anticancer Drugs 2013; 24: 473–83.